{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Maranta N"],"funding":["Ministero dell'Università e della Ricerca","Linnea SA"],"pagination":["74"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12502145"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(1)"],"pubmed_abstract":["Background
The use of Cannabis sativa L. (Cannabis) was reported by observational studies on inflammatory bowel diseases (IBD) patients. However, this indication is poorly supported by clinical trials. Several pre-clinical studies demonstrated the anti-inflammatory activity of Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and cannabidiol (CBD) at intestinal level. On the contrary, minor cannabinoids, such as cannabigerol (CBG), were less investigated. Moreover, several authors suggested that complex Cannabis extracts might display a higher efficacy in respect to pure cannabinoids against inflammatory disorders.Methods
This study was aimed at investigating the role of Cannabis extracts, standardized in CBD and CBG content, in a model of in vitro-induced intestinal inflammation using CaCo"],"journal":["Journal of cannabis research"],"pubmed_title":["Efficacy of non-psychotropic Cannabis sativa L. standardized extracts in a model of intestinal inflammation."],"pmcid":["PMC12502145"],"funding_grant_id":["not applicable"],"pubmed_authors":["Ciriello U","Sangiovanni E","Martinelli G","Fumagalli M","Dell'Agli M","Rossini N","Pozzoli C","Maranta N","Sonzogni E","Piazza S","Paladino G"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of non-psychotropic Cannabis sativa L. standardized extracts in a model of intestinal inflammation.","description":"Background
The use of Cannabis sativa L. (Cannabis) was reported by observational studies on inflammatory bowel diseases (IBD) patients. However, this indication is poorly supported by clinical trials. Several pre-clinical studies demonstrated the anti-inflammatory activity of Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and cannabidiol (CBD) at intestinal level. On the contrary, minor cannabinoids, such as cannabigerol (CBG), were less investigated. Moreover, several authors suggested that complex Cannabis extracts might display a higher efficacy in respect to pure cannabinoids against inflammatory disorders.Methods
This study was aimed at investigating the role of Cannabis extracts, standardized in CBD and CBG content, in a model of in vitro-induced intestinal inflammation using CaCo","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T06:30:21.099Z","creation":"2026-06-01T03:06:45.961Z"},"accession":"S-EPMC12502145","cross_references":{"pubmed":["41053843"],"doi":["10.1186/s42238-025-00335-2"]}}